ATE143803T1 - Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen - Google Patents

Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen

Info

Publication number
ATE143803T1
ATE143803T1 AT93300005T AT93300005T ATE143803T1 AT E143803 T1 ATE143803 T1 AT E143803T1 AT 93300005 T AT93300005 T AT 93300005T AT 93300005 T AT93300005 T AT 93300005T AT E143803 T1 ATE143803 T1 AT E143803T1
Authority
AT
Austria
Prior art keywords
protein
therapeutic protein
orally
oral administration
stabilizing agent
Prior art date
Application number
AT93300005T
Other languages
English (en)
Inventor
J Gabriel Michael
Allen Litwin
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25541237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE143803(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Application granted granted Critical
Publication of ATE143803T1 publication Critical patent/ATE143803T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93300005T 1992-12-22 1993-01-04 Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen ATE143803T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99493292A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
ATE143803T1 true ATE143803T1 (de) 1996-10-15

Family

ID=25541237

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93300005T ATE143803T1 (de) 1992-12-22 1993-01-04 Orale verabreichung von immunologischen aktiven biomolekülen und anderen therapeutischen proteinen

Country Status (12)

Country Link
US (1) US5591433A (de)
EP (1) EP0603992B2 (de)
JP (1) JPH0710771A (de)
AT (1) ATE143803T1 (de)
AU (1) AU664222B2 (de)
CA (1) CA2086631C (de)
DE (1) DE69305313T3 (de)
DK (1) DK0603992T4 (de)
ES (1) ES2095001T5 (de)
GR (2) GR3022090T3 (de)
NZ (1) NZ245618A (de)
SG (1) SG52402A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU664561B2 (en) * 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
HUT76101A (en) * 1994-04-08 1997-06-30 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
EP0867188A1 (de) * 1996-08-20 1998-09-30 Freund Industrial Co., Ltd. Immunogen-enthaltende mikrosphären, verfahren zur herstellung derselben, und verfahren zur immunisierung von tieren unter verwendung derselben
EP0943336A1 (de) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptid-enthaltende Wirkstoffzusammensetzungen zur oralen Verabreichung
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
CA2319437C (en) * 1998-01-31 2009-06-16 University Of Arkansas Methods and reagents for decreasing allergic reactions
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
PT1065936E (pt) 1998-03-23 2009-09-24 Gen Mills Inc Encapsulação de componentes em produtos comestíveis
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9818591D0 (en) * 1998-08-27 1998-10-21 Danbiosyst Uk Pharmaceutical composition
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
CA2396237A1 (en) * 2000-01-07 2001-07-19 Jacob Gabriel Michael Selective activation of a th1 or th2 lymphocyte regulated immune response
GB0002386D0 (en) * 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1272213B1 (de) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbielles wirkstoffabgabesystem
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
EP1335938B1 (de) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein-Konstrukte
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
SK1732004A3 (sk) * 2001-10-15 2005-06-02 R�Hm Gmbh & Co. Kg Použitie kopolyméru na prípravu liekovej formy, ktorá ako účinnú látku obsahuje peptid alebo proteín
KR100469943B1 (ko) * 2002-03-20 2005-02-02 삼성정밀화학 주식회사 장용성 코팅제로 사용되는 아크릴 공중합체의 제조 방법
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
PL1615646T5 (pl) 2003-04-08 2022-12-19 Progenics Pharmaceuticals, Inc. Preparaty farmaceutyczne zawierające metylonaltrekson
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
EP1617846A1 (de) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. Verwendung von peripherern opioid-antagonisten, insbesondere methylnaltrexon zur behandlung des reizdarmsyndroms
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
WO2005123119A2 (en) * 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
JP2008502605A (ja) * 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
BRPI0608818A2 (pt) * 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1933867A1 (de) 2005-10-04 2008-06-25 Alk-Abello A/S Feste impfstoff-formulierung
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007112747A1 (en) * 2006-03-31 2007-10-11 Curalogic A/S Immunogen combinations
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
HUE025662T2 (en) 2007-03-29 2016-04-28 Wyeth Llc Peripheral opioid receptor and antagonists and their uses
EP2137191B8 (de) * 2007-03-29 2016-06-08 Progenics Pharmaceuticals, Inc. Antagonisten der peripheren opioidrezeptoren und ihre verwendung
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP2240489A1 (de) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. HERSTELLUNG UND VERWENDUNG VON (R), (R)-2,2ýBIS-METHYLNALTREXON
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2296683B1 (de) 2008-06-03 2017-01-25 University Of Rochester AvrA PROTEIN ZUR BEHANDLUNG VON ENTZÜNDLICHER DARMERKRANKUNG UND BEHANDLUNG IHRER SYMPTOME
JP5985824B2 (ja) 2008-07-01 2016-09-06 ザ ユニヴァーシティー オヴ シカゴ オピオイド受容体アンタゴニスト含有の粒子および使用方法
JP2010077057A (ja) * 2008-09-25 2010-04-08 Kagoshima Univ 抗食物アレルギーワクチン
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5931449B2 (ja) * 2012-01-11 2016-06-08 日東電工株式会社 医薬組成物及びその製造方法
US10940170B2 (en) 2014-07-07 2021-03-09 University Of Massachusetts Anthelmintic probiotic compositions and methods
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US11484568B2 (en) 2016-01-15 2022-11-01 University Of Massachusetts Anthelmintic compositions and methods
JP7601362B2 (ja) 2017-05-23 2024-12-17 ユニバーシティー オブ マサチューセッツ 純粋な駆虫組成物および関連する方法
US20240252795A1 (en) 2018-11-19 2024-08-01 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE621398A (de) * 1900-01-01
US3143473A (en) * 1961-08-16 1964-08-04 Behringwerke Ag Stable, solid, oral live antipoliomyelitis vaccine compositions and process for preparing them
US3458621A (en) * 1966-08-31 1969-07-29 American Home Prod Tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
US3823228A (en) * 1971-09-29 1974-07-09 Univ Illinois Tge virus vaccine
US3860490A (en) * 1972-02-11 1975-01-14 Nat Patent Dev Corp Process of subjecting a microorganism susceptible material to a microorganism
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4269764A (en) * 1979-08-02 1981-05-26 Roy Patterson Preparation for treatment of allergic patients sensitive to ragweed pollen
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
JPS56142211A (en) * 1980-04-09 1981-11-06 Riken Vitamin Co Ltd Production of enteric preparation
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
GB8321178D0 (en) * 1983-08-05 1983-09-07 Beecham Group Plc Compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4794000A (en) * 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (de) * 1985-01-19 1987-09-02 Beecham Group Plc Allergene enthaltende Arzneimittel mit magensaftresistentem Überzug
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPS6417A (en) * 1987-02-20 1989-01-05 Shikoku Chem Corp Chemotherapeutic agent composition
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
DE69001898T2 (de) * 1989-03-17 1993-09-23 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
EP0527940A1 (de) * 1990-05-08 1993-02-24 Liposome Technology, Inc. Direkt sprühgetrocknetes arzneistoff/lipid pulver
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
HUT69942A (en) * 1990-10-15 1995-09-28 Brigham & Womens Hospital Treatment of autoimmun diseases by oral administration of autoantigenes
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
AU664561B2 (en) † 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release

Also Published As

Publication number Publication date
ES2095001T3 (es) 1997-02-01
AU664222B2 (en) 1995-11-09
GR3035452T3 (en) 2001-05-31
US5591433A (en) 1997-01-07
DE69305313T3 (de) 2001-06-21
DK0603992T4 (da) 2001-03-05
ES2095001T5 (es) 2001-03-16
EP0603992A1 (de) 1994-06-29
GR3022090T3 (en) 1997-03-31
JPH0710771A (ja) 1995-01-13
SG52402A1 (en) 1998-09-28
DK0603992T3 (da) 1997-03-24
EP0603992B1 (de) 1996-10-09
AU3104593A (en) 1994-07-07
NZ245618A (en) 1994-10-26
EP0603992B2 (de) 2000-12-06
DE69305313T2 (de) 1997-02-20
DE69305313D1 (de) 1996-11-14
CA2086631C (en) 1998-10-06
CA2086631A1 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
DE69305313D1 (de) Orale Verabreichung von immunologischen aktiven Biomolekülen und anderen therapeutischen Proteinen
ATE158180T1 (de) Oral verabreichbare therapeutische proteine und herstellungsverfahren
RU93004764A (ru) Амиды сульфамидо- и сульфамидокарбонилпиридин-2-карбоновых кислот, их пиридин-n-оксиды, способ их получения и их применение в качестве лекарственных препаратов
NO964864L (no) Orale, flytende alendronatpreparater
DE69434418D1 (de) Orale Dareichungsform
IS3644A7 (is) Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
RU93011229A (ru) Биомасса для удаления волос
RU93009804A (ru) Вакцина против эшерихиоза животных
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
RU94028204A (ru) Препарат "уберсан" для лечения мастита у сельскохозяйственных животных
RU2099061C1 (ru) Способ лечения нейродермита
RU1808324C (ru) Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т
DE2640707C3 (de) Verfahren zur Herstellung von Arzneipräparaten mit einem Gehalt an von im Darm resorbierbaren Protein und Peptidlösungen
RU94019564A (ru) Способ лечения желудочно-кишечных заболеваний
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
RU97117569A (ru) Гастроветин
RU2000126015A (ru) Лекарственное средство для лечения и профилактики болезней, вызываемых недостаточностью селена в организме сельскохозяйственных животных
RU2001106744A (ru) Способ профилактики и лечения мастита у коров
RU94012402A (ru) Способ лечения синдрома раздраженной кишки
RU93056259A (ru) Средство для лечения диспепсии телят
RU95105357A (ru) Способ лечения пищевой аллергии
RU94016573A (ru) Препарат для лечения и профилактики мастита крупного рогатого скота в сухостойный период
RU98119939A (ru) Лекарственное средство и способ стимуляции иммунитета у больных острыми воспалительными заболеваниями придатков матки

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee